Epic Systems has been challenged in court before, but it’s different this time

Also: Pfizer pulls sickle cell treatment Oxbryta off global markets

September 26, 2024 Check out STAT+

Sponsored By

For World Alzheimer's Day, get your first 3 months of STAT+ for $20 and stay up-to-date on Alzheimer's disease and treatment. Learn more here.

Adobe STAT+ | Epic Systems has been challenged in court before, but it's different this time Particle Health's antitrust lawsuit is a direct threat to Epic Systems' dominance in the multibillion-dollar market for health data. By Casey Ross STAT+ | Why Biohaven will test the FDA's regulatory limits   If the FDA accepts the company's application for a rare disease drug, the review next year will be a fascinating exercise in regulatory navel gazing. By Adam Feuerstein Can MRIs ensure prostate cancer screening does more good than harm? A study finds that the harms of overdiagnosing prostate cancer is lessened when MRI is used as well as PSA tests. By Angus Chen Annice Lyn/Getty Images STAT+ | Sleep apnea alert on Apple Watch: What does it mean, and how does it work? Technology experts and doctors help unpack the science and data behind Apple Watch's latest health tech feature. By Mario Aguilar STAT+ | Biden administration axes proposal to mandate more drug price transparency in Medicaid The proposal could have helped states drive harder bargains with pharmaceutical companies. By Bob Herman STAT+ | FDA introduces plan to assess safety of common chemicals added to food Many details remain unclear, such as which of the additives food companies use to enhance color, texture, and durability will be examined. By Lizzy Lawrence Lee Klafczynski for STAT STAT+ | What Pfizer's decision to pull its sickle cell drug means for patients, the company, and the FDA The move, based on safety concerns, embarrassed Pfizer, and raised questions about decisions by Global Blood Therapeutics, which developed Oxbryta. By Matthew Herper, Andrew Joseph, Lizzy Lawrence, Adam Feuerstein, and Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser